← Back to Search

"OncoTool" Intervention for Communication

N/A
Waitlist Available
Led By Betina Yanez
Research Sponsored by Northwestern University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up t1 (prior to starting intervention), biweekly during the 8 week intervention, t2 (8 weeks post intervention), t3 (6 months post-intervention)
Awards & highlights

Study Summary

Oncotool for Cancer Medications

Eligible Conditions
  • Communication
  • Tyrosine Kinase Inhibitor
  • Cancer
  • Medication Adherence

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~t1 (prior to starting intervention), biweekly during the 8 week intervention, t2 (8 weeks post intervention), t3 (6 months post-intervention)
This trial's timeline: 3 weeks for screening, Varies for treatment, and t1 (prior to starting intervention), biweekly during the 8 week intervention, t2 (8 weeks post intervention), t3 (6 months post-intervention) for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Change in Health Related Quality of Life will be evaluated with The Functional Assessment of Cancer Therapy (FACT-G7)
Change in Self Reported Adherence to TKIs will be evaluated with the ARMS questionnaire.
Electronically Verified TKI Adherence will be measured using medication event monitoring systems (MEMS)
+1 more
Secondary outcome measures
Cancer Related Communication and Attitudinal Self Efficacy will be evaluated using the Communication and Attitudinal Self-Efficacy scale for cancer (CASE-cancer)
Cancer-Specific Distress will be evaluated using The Impact of Event Scale (IES)
Emotional Social Support is assessed using the emotional subscale portion of the Medical Outcomes Study - Social Support Survey Instrument (MOS-SSS)
+4 more

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: "OncoTool" InterventionExperimental Treatment1 Intervention
Group II: "Oncotool" ControlActive Control1 Intervention
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Oncotool Intervention (symptom reporting + TKI education)
2020
N/A
~90

Find a Location

Who is running the clinical trial?

Northwestern UniversityLead Sponsor
1,585 Previous Clinical Trials
917,148 Total Patients Enrolled
3 Trials studying Communication
1,109 Patients Enrolled for Communication
Betina YanezPrincipal Investigator - Northwestern University
Northwestern University

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Oncotool for Cancer Medications
Betina Yanez 2020. "Oncotool for Cancer Medications". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03952312.
~16 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top